thyroid cancer
Conditions
Interventions
lenvatinib treatment group:lenvatinib treatment
Sponsors
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Malignant tumors derived from thyroid follicular epithelium, including differentiated thyroid cancer, poorly differentiated cancer, and anaplastic cancer; 2. Inoperable patients: (1) Differentiated thyroid cancer cannot undergo radical surgery, which will seriously affect the quality of life of the patients and cause high-risk complications after surgery; (2) The poorly differentiated carcinoma and undifferentiated carcinoma that cannot be radically removed by surgery.
Exclusion criteria
Exclusion criteria: 1. Aged > 70 years or < 18 years; 2. Combining surgical contraindications; 3. Contraindications for combined lenvatinib treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of lenvatinib neoadjuvant therapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Surgical resection rate;partial remission;complete remission;stable disease;progression disease;progression free survival;overall survival; | — |
Countries
China
Contacts
Public ContactWensheng Liu
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Outcome results
None listed